GenSight Biologics Withdraws its EMA Application for LUMEVOQ®

GenSight Biologics to Host a Webcast on April 5, 2023, to Provide an Update on LUMEVOQ® Manufacturing Following Investigations Findings

GenSight Biologics Reports Full Year 2022 Consolidated Financial Results

GenSight Biologics to Present at Upcoming Medical Conferences

GenSight Biologics Provides Update on LUMEVOQ® Manufacturing and Commercialization Timelines

GenSight Biologics Announces its 2023 Financial Calendar

GenSight Biologics announces the drawdown of the first EUR 8 million tranche under its credit agreement with the European Investment Bank

GenSight Biologics Reports Cash Position as of December 31, 2022, FY 2022 Revenues and Provides Business Update

GenSight Biologics secures €12 Million financing through a premium convertible notes issuance to an institutional investor and provides business update

GenSight Biologics secures a €35 million credit facility from the European Investment Bank to support the launch of LUMEVOQ® in Europe